内皮細胞におけるマリック酵素1の不活性化は,肺高血圧を緩和する
Ya Luo1,2,3, Xianmei Qi1,2, Zhenxi Zhang4,2
1State Key Laboratory of Respiratory Health and Multimorbidity (Y.L., X.Q., J.Z., B.L., T.S., X.L., H.H., J.L., Q.T., Y.Z., J.P., P.Y., Y.X., J.W., C.W.).
Circulation
|February 5, 2024
まとめ
マリック酵素1 (ME1) の上調は,内皮細胞機能を乱すことで肺高血圧 (PH) を誘発する. ME1の抑制はアデノシン生成を促進し,PHの潜在的な治療戦略を提供します.
科学分野:
- 心血管生物学
- 代謝の調節
- 肺血管疾患
背景:
- 肺高血圧 (PH) は,代謝不調に関連した重症疾患です.
- PH病原化の正確な細胞メカニズムは不明である.
- マリック酵素1 (ME1) は,糖分解とTCAサイクルを結びつける重要な代謝酵素である.
研究 の 目的:
- 肺高血圧の発生におけるME1の役割とメカニズムを調査する.
- ME1をPHの治療対象として検討する.
主な方法:
- 全球および内皮特異的なME1ノックアウトマウスモデルを使用した.
- 小型ヘアピンRNAとME1阻害体 (ME1*) を肺動脈内皮細胞で使用した.
- メタボロミクスとシーホースの代謝分析を行った.
- ME1*の治療効果をPH動物モデルで評価した.
主要な成果:
- ME1の発現と活性がPH肺組織で上昇した.
- ME1 ノックアウトが弱まった低酸素またはSuHx誘発PH.
- ME1の内皮切除は,肺血管の改造から守られています.
- ME1の抑制によりアデノシン生成が強化され,A2A受容体のシグナル伝達が活性化され,酸化窒素が増加し,炎症が軽減された.
結論:
- 内皮細胞におけるME1のアップレギュレーションはPHの病原性の重要な要因である.
- ME1抑制はアデノシン信号を回復することによって内皮機能を正常化する.
- ME1はPH治療の有望な治療目標です.
関連する概念動画
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
165
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
167
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
158
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
158
01:30Pulmonary Hypertension: Classification and Pathogenesis
180
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
180
01:23Antihypertensive Drugs: Vasodilators
525
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
525
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
182
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
182